Pira Inhibitors
Pira inhibitors represent a class of chemical compounds characterized by their ability to interfere with the activity of a specific enzyme or group of enzymes within a particular metabolic pathway. These inhibitors are designed based on the understanding of enzyme kinetics and the molecular structure of the target proteins. The design of such inhibitors typically involves the creation of molecules that can bind to the active site of the enzyme or to an allosteric site, which is a different location on the enzyme that can modulate its activity. This binding can be competitive, non-competitive, or uncompetitive, depending on whether the inhibitor resembles the substrate of the enzyme, and whether it binds to the enzyme, the enzyme-substrate complex, or both.
The specificity of Pira inhibitors is of paramount importance, as it determines their effectiveness and the extent of their interaction with the intended enzyme. They are often structurally similar to the substrates or transition states of the enzymes they target, allowing them to fit snugly into the enzyme's active site. This structural mimicry is key to their inhibitory function, as it enables them to effectively compete with the natural substrate for binding to the enzyme. The development of Pira inhibitors involves a meticulous process of molecular design, often utilizing computational models to predict how the inhibitor will interact with the enzyme. This is followed by synthesis and iterative testing to refine the inhibitor's structure for optimal interactions. The ultimate goal is to achieve a high degree of selectivity to ensure that the inhibitor affects only the intended enzyme, thereby limiting any off-target effects that could arise from interaction with other proteins.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 can prevent the activation of the AKT signaling pathway, which may lead to decreased activity of Pira if Pira is downstream of AKT. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the ERK/MAPK pathway. Inhibition of MEK prevents ERK activation, potentially reducing Pira activity if it is regulated by the ERK/MAPK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in stress responses. If Pira operates downstream of p38 MAP kinase or is modulated by stress-activated pathways, this inhibitor could lead to reduced Pira activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR), which is a central regulator of cell growth and proliferation. If Pira is involved in pathways regulated by mTOR, rapamycin could diminish its functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which participates in the regulation of apoptosis and cell differentiation. Inhibition of JNK could impact Pira activity if Pira is associated with these cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, like LY294002, and it also blocks the activation of AKT. This could indirectly lead to reduced activity of Pira if it is influenced by the PI3K/AKT pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, functioning similarly to PD98059 by potentially decreasing Pira activity through the inhibition of the ERK/MAPK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases, which are involved in various signaling pathways, including those regulating cell growth and survival. Inhibition of these kinases may decrease Pira activity if Pira is a downstream effector. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, also targeting Src family kinases. It could indirectly reduce Pira functional activity by altering signaling pathways that involve these kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect numerous cellular processes, including the degradation of signaling proteins. If Pira stability or function is dependent on proteasome activity, bortezomib could lead to its functional inhibition. | ||||||